Webinar: Economics Behind the Commercialization of an AMR Product – Understanding the Issues and Fixing it
Thursday 7 May 05:00 – 06:00 PM CET
Speaker: Dr Ryan Cirz
Dr Maarten van Dongen & Dhanuraj (Raj) Shetty
The goal of this webinar was to provide insight into the economic fundamentals and post marketing commitments, inventory build and quality assurance, sales and marketing and additional economic considerations of the challenging antimicrobials market.
According to the World Health Organization, the health and economic consequences of antimicrobial resistance are considerable and costly, making it a serious threat to societal health. As resistance to antibiotics grows there is a well-recognized misalignment between the clinical need for new antibiotics and the incentives for their development as the returns from investment in antibiotics research and development (R&D) is perceived too small. The recent failure of small cap biotech’s such as Achaogen, reflect the systemic problems that have been driving huge losses, hidden inside of large pharma, for decades.
The commercial model for antibiotics is evolving. There is a growing awareness that AMR focused companies with newly approved antibiotics face substantial economic challenges. Considering the dynamics there is concern that there is a general lack of understanding of the mechanics during the collapse of the industry.
Dr Ryan Cirz is an independent consultant. Previously, he was founder and vice President of Research at Achaogen. Achaogen focused on discovering, developing and commercializing innovative antibacterials to treat multi-drug resistant (MDR) Gram-negative infections. Here, he participated in and led the advancement of four home-grown antibacterial assets through investigational new drug applications. Three of those programs advanced into the clinic with two advancing past phase I studies and one through US approval in 2018.
At Achaogen, he oversaw the early-stage (pre-investigational new drug) pipeline and provided intellectual insight/support to all things related to infectious diseases including late stage development, commercialization and medical affairs.
Ryan has a background in molecular biology and bacterial genetics, is passionate about medicinal chemistry in terms of scaffold design, lead optimization and selection and is well-versed in the broad scientific, policy and commercial challenges. He has led the non-clinical portion of Achaogen and the Biomedical Advanced Research and Development Authority’s collaboration on Plazomicin which required the design and execution of non-human primate efficacy studies on Plazomicin for the treatment of Centers for Disease Control and Prevention (CDC) category A agents.
Ryan was a graduate researcher at the Scripps Research Institute in California, US. He was awarded his PhD in Biochemistry from The Scripps Research Institute and his BSc in biochemistry and molecular biology from Penn State University, Pennsylvania, US.